Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma

References

• Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407–1427. doi:10.1093/jnci/dji08016204691
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447–1463. doi:10.1210/jcem.86.4.740711297567
   PubMed Web of Science ®Google Scholar
• Ohori NP, Schoedel KE. Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the Bethesda system for reporting thyroid cytopathology: sources and recommendations. Acta Cytol. 2011;55:492–498. doi:10.1159/00033421822156456
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390–3397. doi:10.1210/jc.2011-146921880806
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092–2098. doi:10.1210/jc.2009-024719318445
   PubMed Web of Science ®Google Scholar
• Beaudenon-Huibregtse S, Alexander EK, Guttler RB, et al. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules. Thyroid. 2014;24:1479–1487. doi:10.1089/thy.2013.064024811481
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. doi:10.1089/thy.2015.037326462967
   PubMed Web of Science ®Google Scholar
• Galuppini F, Pennelli G, Vianello F, et al. BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience. Clin Chem Lab Med. 2016;54:1531–1539. doi:10.1515/cclm-2015-021826863344
   PubMed Web of Science ®Google Scholar
• Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373–6379. doi:10.1210/jc.2005-098716174717
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Narkar A, Mukhopadhyaya R, et al. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol. 2012;23:83–93. doi:10.1007/s12022-011-9184-522105775
   PubMed Web of Science ®Google Scholar
• Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012;118:1764–1773. doi:10.1002/cncr.2652321882184
   PubMed Web of Science ®Google Scholar
• Bartolazzi A, Orlandi F, Saggiorato E, Italian Thyroid Cancer Study Group (ITCSG), et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 9;2008:543–549. doi:10.1016/S1470-2045(08)70132-318495537
   PubMed Web of Science ®Google Scholar
• Yasuda M, Schmid T, Rübsamen D, et al. Downregulation of programmed cell death 4 by inflammatory conditions contributes to the generation of the tumor promoting microenvironment. Mol Carcinog. 2010;49:837–848. doi:10.1002/mc.2060820607724
   PubMed Web of Science ®Google Scholar
• Fassan M, Realdon S, Pizzi M, et al. Programmed cell death 4 nuclear loss and miR-21 or activated Akt overexpression in esophageal squamous cell carcinogenesis. Dis Esophagus. 2012;25:263–268. doi:10.1111/j.1442-2050.2011.01236.x21883657
   PubMed Web of Science ®Google Scholar
• Frankel LB, Christoffersen NR, Jacobsen A, et al. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008;283:1026–1033. doi:10.1074/jbc.M70722420017991735
   PubMed Web of Science ®Google Scholar
• Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2009;11:141–147. doi:10.1038/ni.182819946272
   PubMed Web of Science ®Google Scholar
• Yang HS, Jansen AP, Nair R, et al. A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NFkappaB or ODC transactivation. Oncogene. 2001;21:669–676. doi:10.1038/sj.onc.1204137
   Google Scholar
• UICC. Thyroid gland In: Brierly JD, Gospodarowicz MK, Wittekind C editors, TNM Classification of Malignant Rumours, 8th ed. Oxford, UK: Wiley-Blackwell Publishers; 2018:51–54.
   Google Scholar
• Sapio MR, Posca D, Troncone G, et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol. 2006;154:341–348. doi:10.1530/eje.1.0207216452550
   PubMed Web of Science ®Google Scholar
• Pennelli G, Fassan M, Mian C, et al. PDCD4 expression in thyroid neoplasia. Virchows Arch. 2013;462:95–100. doi:10.1007/s00428-012-1352-623212265
   PubMed Web of Science ®Google Scholar
• Fassan M, Pizzi M, Battaglia G, et al. Programmed cell death 4 (PDCD4) expression during multistep Barrett’s carcinogenesis. J Clin Pathol. 2010;63:692–696. doi:10.1136/jcp.2010.07825320702469
   PubMed Web of Science ®Google Scholar
• Mudduluru G, Medved F, Grobholz R, et al. Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer. 2007;110:1697–1707. doi:10.1002/cncr.2281217849461
   PubMed Web of Science ®Google Scholar
• Fassan M, Pizzi M, Giacomelli L, et al. PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis. Virchows Arch. 2011;458:413–419. doi:10.1007/s00428-011-1046-521279518
   PubMed Web of Science ®Google Scholar
• Fassan M, Volinia S, Palatini J, et al. MicroRNA expression profiling in human Barrett’s carcinogenesis. Int J Cancer. 2011;129:1661–1670. doi:10.1002/ijc.2582321128279
   PubMed Web of Science ®Google Scholar
• Mian C, Pennelli G, Fassan M, et al. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid. 2012;22:890–896. doi:10.1089/thy.2012.004522747440
   PubMed Web of Science ®Google Scholar
• Zatelli MC, Trasforini G, Leoni S, et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol. 2009;161:467–473. doi:10.1530/EJE-09-035319574281
   PubMed Web of Science ®Google Scholar
• Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393–4397. doi:10.1210/jc.2003-03030512970315
   PubMed Web of Science ®Google Scholar
• Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625–627. doi:10.1093/jnci/95.8.62512697856
   PubMed Web of Science ®Google Scholar
• Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22:6455–6457. doi:10.1038/sj.onc.120673914508525
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–5404. doi:10.1210/jc.2003-03083814602780
   PubMed Web of Science ®Google Scholar
• Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 2004;23:7436–7440. doi:10.1038/sj.onc.120744415273715
   PubMed Web of Science ®Google Scholar
• Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch. 2005;446:589–595. doi:10.1007/s00428-005-1236-015902486
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28:742–762. doi:10.1210/er.2007-000717940185
   PubMed Web of Science ®Google Scholar
• Damiani L, Lupo S, Rossi R, et al. Evaluation of the role of BRAFV600E somatic mutation on papillary thyroid cancer disease persistence: a prospective study. Eur Thyroid J. 2018;7(5):251–257. doi:10.1159/00049069930374428
   PubMed Web of Science ®Google Scholar
• Shen G, Kou Y, Liu B, Huang R, Kuang A. The BRAFV600E mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy? Nucl Med Commun. 2019;40(1):8–13. doi:10.1097/MNM.000000000000093030312216
   PubMed Web of Science ®Google Scholar
• Fassan M, Cagol M, Pennelli G, et al. Programmed cell death 4 protein in esophageal cancer. Oncol Rep. 2010;24:135–139. doi:10.3892/or_0000083820514454
   PubMed Web of Science ®Google Scholar
• Pennelli G, Galuppini F, Barollo S, et al. The PDCD4/miR-21 pathway in medullary thyroid carcinoma. Human Pathol. 2015;46:50–57. doi:10.1016/j.humpath.2014.09.00625316501
   PubMed Web of Science ®Google Scholar
• Chen X, Wu W, Chen X, Gong X. Roles of phosphatidylinositol 3-kinase regulatory subunit alpha, activator protein-1, and programmed cell death 4 in diagnosis of papillary thyroid carcinoma. Tumour Biol. 2016;37(5):6519–6526. doi:10.1007/s13277-015-4476-x26637226
   PubMedGoogle Scholar
• Wei C, Song H, Sun X, et al. miR-183 regulates biological behavior in papillary thyroid carcinoma by targeting the programmed cell death 4. Oncol Rep. 2015;34(1):211–220. doi:10.3892/or.2015.397126063221
   PubMed Web of Science ®Google Scholar
• Vinh-Hung V, Verkooijen HM, Fioretta G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009;27:1062–1068. doi:10.1200/JCO.2008.18.696519164210
   PubMed Web of Science ®Google Scholar
• Li J, Zhang S, Zheng S, et al. The BRAF V600E mutation predicts poor survival outcome in patients with papillary thyroid carcinoma: a meta analysis. Int J Clin Exp Med. 2015;8:22246–22253. 26885200
   PubMed Web of Science ®Google Scholar